← back to search

Joshua T. Schiffer

Fred Hutch Cancer Center ·
Area of research
Epidemiology · Infectious Diseases
Research interest
Dr. Joshua Schiffer is an infectious disease physician and researcher who develops mathematical models to address significant medical challenges. A major focus of his work is to analyze strategies to achieve an HIV cure in people who require antiviral drugs for their entire lifetime, due to reservoirs of latent virus. These models assess the potential of a wide variety of potential curative technologies. Dr. Schiffer and colleagues also use mathematical modeling to study how T cells help control numerous herpes viruses that cause disease in healthy people and in cancer patients with compromised immune systems. They develop models to explain when and how latent viruses reactivate and use models to optimize the effectiveness of antiviral drugs. His team is also focusing on COVID-19, including developing models of the immune response against the coronavirus and the best treatment strategies.
h-index
45
citations
7,518
works
284
NIH funding
primary concept
Medicine
email

Recent publications

Mild HIV-specific selective forces overlaying natural CD4+ T cell dynamics explain the clonality and decay dynamics of HIV reservoir cells
Cell Systems 2025cited by 1position: middledoi
Impact of misclassified defective proviruses on HIV reservoir measurements
Nature Communications 2023cited by 41position: middledoi
Estimating the contribution of CD4 T cell subset proliferation and differentiation to HIV persistence
Nature Communications 2023cited by 26position: middledoi
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Nature Communications 2023cited by 22position: middledoi
The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial
Open Forum Infectious Diseases 2023cited by 20position: middledoi
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
New England Journal of Medicine 2021cited by 1,269position: middledoi
Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation
Blood 2021cited by 156position: middledoi
Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial
EClinicalMedicine 2021cited by 65position: middledoi
Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART
PLoS Pathogens 2021cited by 51position: middledoi
Longitudinal study reveals HIV-1–infected CD4+ T cell dynamics during long-term antiretroviral therapy
Journal of Clinical Investigation 2020cited by 92position: middledoi
A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation
Nature Communications 2018cited by 150position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Daniel B. Reeves · Dartmouth College6 papers (2018–2025)Steven G. Deeks · University of California, San Francisco5 papers (2020–2025)Rebecca Hoh · World Wide Web Consortium4 papers (2020–2025)Frederick Hecht · University of California, San Francisco3 papers (2020–2023)Peter W. Hunt · University of California, San Francisco2 papers (2021–2023)Jeffrey N. Martin · Global Solutions for Infectious Diseases2 papers (2021–2023)Charline Bacchus-Souffan · VIR Biotechnology (United States)2 papers (2021–2023)Janet D. Siliciano · Howard Hughes Medical Institute2 papers (2020–2025)Elizabeth R. Duke · Fred Hutch Cancer Center2 papers (2018–2021)Adam M. Spivak · University of Utah2 papers (2018–2023)Michael J. Peluso · Cardiff University2 papers (2023–2025)Marc K. Hellerstein · University of California, Berkeley2 papers (2021–2023)Danielle Rigau · Johns Hopkins Medicine2 papers (2020–2025)Mars Stone · VIR Biotechnology (United States)2 papers (2021–2023)Mark Fitch · University of California, Berkeley2 papers (2021–2023)Mohamed Abdel‐Mohsen · The Wistar Institute2 papers (2021–2023)Joseph M. McCune · Gates Foundation2 papers (2021–2023)Haelee Ahn · University of California, San Francisco2 papers (2021–2023)Robert F. Siliciano · University of Baltimore2 papers (2020–2025)Annukka A.R. Antar · Boston University2 papers (2020–2025)